Lymphatic malformation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lymphatic malformation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations https://clinicaltrials.eu/trial/study-of-rly-2608-for-adults-and-children-with-pik3ca-related-overgrowth-and-malformations/ Wed, 29 Apr 2026 15:04:57 +0000 https://clinicaltrials.eu/trial/study-of-rly-2608-for-adults-and-children-with-pik3ca-related-overgrowth-and-malformations/ This clinical trial is focused on studying a condition known as PIK3CA Related Overgrowth Spectrum and malformations caused by a mutation in the PIK3CA gene. The trial will explore the effects of a new treatment called RLY-2608, which is taken as a capsule. This treatment is designed to target and inhibit a specific protein that is affected by the PIK3CA mutation, potentially helping to manage the symptoms associated with this condition.

The purpose of the study is to determine the best dose of RLY-2608 for different groups of participants and to assess its safety and effectiveness. The study will be conducted in several parts. Initially, participants will receive RLY-2608 to find the most suitable dose and to monitor any side effects. In a later part of the study, the effectiveness of RLY-2608 will be compared to a placebo to see how well it works in reducing the size of the overgrowths or malformations.

Participants in the study will be monitored over a period of time to observe any changes in their condition and to ensure their safety. The study aims to provide valuable information on how RLY-2608 can be used to treat individuals with conditions driven by the PIK3CA mutation, potentially leading to improved treatment options in the future.

]]> Study on the Effects of Topical Sirolimus for Lingual Microcystic Lymphatic Malformations in Children and Adults https://clinicaltrials.eu/trial/study-on-the-effects-of-topical-sirolimus-for-lingual-microcystic-lymphatic-malformations-in-children-and-adults/ Wed, 29 Apr 2026 15:00:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-topical-sirolimus-for-lingual-microcystic-lymphatic-malformations-in-children-and-adults/ This clinical trial is focused on studying a rare condition known as lingual microcystic lymphatic malformations (LMLMs). These are unusual vascular malformations that appear as clusters of cysts filled with lymph fluid or blood. They can cause significant issues, even if the lesions are small, such as oozing, bleeding, infections, and difficulties with speech, chewing, or breathing. Pain and cosmetic concerns are also common. The treatment being tested in this study is a solution called sirolimus, which is applied topically, meaning it is put directly on the affected area.

The purpose of the study is to evaluate how effective and safe the 1 mg/mL sirolimus solution is when applied once daily to the front part of the tongue affected by LMLMs in both children and adults. Participants will be observed over a period of 24 weeks, with assessments at various intervals: 4, 8, 12, 16, 20, and 24 weeks. During the study, the effects of the sirolimus solution will be compared to usual care, which involves no treatment. The study aims to see if there is an improvement in the condition of the LMLMs and to monitor any side effects that may occur.

Throughout the study, participants will have their condition evaluated by experts using photographs and will also provide their own assessments of symptoms like oozing, bleeding, and discomfort. The study will also look at the overall quality of life and any changes in the size of the lesions. Safety is a key focus, with regular checks for any adverse effects and monitoring of sirolimus levels in the blood. This trial seeks to provide valuable information on whether topical sirolimus can be a beneficial treatment for those with LMLMs.

]]> Study on Sirolimus for Treating Cervico-facial Lymphatic Malformations in Patients with Poor Prognosis https://clinicaltrials.eu/trial/study-on-sirolimus-for-treating-cervico-facial-lymphatic-malformations-in-patients-with-poor-prognosis/ Wed, 29 Apr 2026 14:57:29 +0000 https://clinicaltrials.eu/trial/study-on-sirolimus-for-treating-cervico-facial-lymphatic-malformations-in-patients-with-poor-prognosis/ This clinical trial is focused on studying the effects of the medication Rapamycin on a condition known as cervico-facial lymphatic malformations, which are abnormal growths of the lymphatic system in the head and neck area. These malformations can be challenging to treat and may lead to significant health issues. The purpose of the study is to evaluate how well Rapamycin can reduce the size of these malformations.

Participants in the study will receive Rapamycin in the form of an oral solution. The study will monitor the changes in the size of the malformations over time, specifically looking for a reduction in volume. The study will also involve regular check-ups and imaging tests, such as MRI scans, to assess the progress of the treatment. The study aims to determine if Rapamycin can effectively decrease the size of the malformations and improve the symptoms associated with them.

Throughout the study, the safety and any side effects of Rapamycin will be closely monitored. Participants will undergo evaluations at different intervals, including 3 months, 6 months, and 12 months, to track the response to the treatment. The study will also explore how Rapamycin affects certain proteins and factors in the body that are related to the growth of these malformations. This research hopes to provide valuable insights into the potential benefits of Rapamycin for individuals with cervico-facial lymphatic malformations.

]]>